Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kramer

Showing results (211-220 of 240) with videos related to

Pageof 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2014
Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trialChristoph Röllig, Martin Bornhäuser, Michael Kramer, et al.
Science (New York, N.Y.)|January 18, 2024
A pulsar in a binary with a compact object in the mass gap between neutron stars and black holesEwan D Barr, Arunima Dutta, Paulo C C Freire, et al.
The Lancet. Oncology|November 17, 2018
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trialUwe Platzbecker, Jan Moritz Middeke, Katja Sockel, et al.
Science (New York, N.Y.)|April 27, 2013
A massive pulsar in a compact relativistic binaryJohn Antoniadis, Paulo C C Freire, Norbert Wex, et al.
Journal of Cancer Research and Clinical Oncology|September 28, 2022
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registryMaher Hanoun, Leo Ruhnke, Michael Kramer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2021
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 MutationsFelix C Saalfeld, Carina Wenzel, Petros Christopoulos, et al.
Haematologica|June 16, 2022
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learningJan-Niklas Eckardt, Christoph Röllig, Klaus Metzeler, et al.
British Journal of Haematology|February 2, 2021
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative StudySabine Kayser, Robert K Hills, Ralitsa Langova, et al.
British Journal of Cancer|August 4, 2023
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experienceJulius C Enßle, Sebastian Wolf, Sebastian Scheich, et al.
Blood|December 8, 2025
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, et al.
Pageof 24

Showing results (211-220 of 240) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2014
Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trialChristoph Röllig, Martin Bornhäuser, Michael Kramer, et al.
Science (New York, N.Y.)|January 18, 2024
A pulsar in a binary with a compact object in the mass gap between neutron stars and black holesEwan D Barr, Arunima Dutta, Paulo C C Freire, et al.
The Lancet. Oncology|November 17, 2018
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trialUwe Platzbecker, Jan Moritz Middeke, Katja Sockel, et al.
Science (New York, N.Y.)|April 27, 2013
A massive pulsar in a compact relativistic binaryJohn Antoniadis, Paulo C C Freire, Norbert Wex, et al.
Journal of Cancer Research and Clinical Oncology|September 28, 2022
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registryMaher Hanoun, Leo Ruhnke, Michael Kramer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2021
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 MutationsFelix C Saalfeld, Carina Wenzel, Petros Christopoulos, et al.
Haematologica|June 16, 2022
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learningJan-Niklas Eckardt, Christoph Röllig, Klaus Metzeler, et al.
British Journal of Haematology|February 2, 2021
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative StudySabine Kayser, Robert K Hills, Ralitsa Langova, et al.
British Journal of Cancer|August 4, 2023
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experienceJulius C Enßle, Sebastian Wolf, Sebastian Scheich, et al.
Blood|December 8, 2025
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, et al.
Pageof 24